Electrolyte Imbalance Risk in AML Chemotherapy

Primary Mechanisms of Electrolyte Disturbance

Patients with excessive leukocytosis at presentation are at particular risk of tumor lysis syndrome under induction chemotherapy, which causes hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia from massive release of intracellular contents 1, 2.
This risk is highest in patients with high white blood cell counts (>100,000/μL) and requires aggressive hydration at 2.5-3 liters/m²/day and rasburicase to prevent hyperuricemia and subsequent renal failure 1, 3.
Appropriate monitoring of electrolytes, BUN, creatinine, uric acid, and phosphate is required at least daily during active treatment 4.

Chemistry profile including electrolytes, BUN, creatinine, uric acid, and phosphate must be obtained at least daily during active treatment 4.
CBC and platelets should be monitored daily during chemotherapy, with differentials daily during chemotherapy and every other day after WBC recovery >500/μL 4.
Patients require central intravenous lines for intensive chemotherapy, necessitating careful fluid and electrolyte management 2, 5.

Patients with WBC >100,000/μL with leukostasis symptoms require emergency leukapheresis coordinated with chemotherapy start and are at highest risk for tumor lysis syndrome 1, 2, 6.
Hydroxyurea at 50-60 mg/kg per day may be used until WBC decreases to <10-20 × 10⁹/L 3.

Do not delay chemotherapy initiation in patients with hyperleukocytosis while attempting to correct electrolytes—coordinate leukapheresis with immediate chemotherapy start 1, 2.
Ensure adequate hydration and uric acid control before initiating chemotherapy in high-risk patients to prevent tumor lysis syndrome 1, 3.